This bulletin focuses on gliclazide modified release and provides the rationale for new patients to be commenced on gliclazide standard release, and for current patients to be considered for a switch to either metformin or gliclazide (or both depending on where the patient is on the treatment pathway). It also reviews the use of metformin modified release and offers advice on switching appropriate patients to standard release metformin.
